OSR HOLDINGS INC (OSRH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.28+136.05%
Close 2026-08-31 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OSRH
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue advancing strategic partnerships and licensing deals, including the global exclusive license for VXM01 with BCM Europe, to grow biopharma portfolio and value.
Stated as a priority in 3 of last 3 quarters. Management executed a definitive $815 million global exclusive license agreement for VXM01 with BCM Europe by 2026-Q2, building on prior term sheets. Revenue declined from $484K in 2026-Q1 to $316K in 2026-Q2, reflecting ongoing development stage. The trajectory shows continued focus on M&A and licensing as a growth strategy.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'This agreement establishes a clear, accountable framework for the development of VXM01.'”
“Announced revised global exclusive license arrangement for VXM01 with BCME.”
“Entered into binding term sheet with BCME for VXM01 license.”
Continue managing capital structure through private placements, note purchase agreements, and related financial obligations to support operations and growth.
Stated as a priority in 3 of last 3 quarters. Management has actively managed capital allocation through private placements and note issuances, including amendments to stock purchase agreements in 2026-Q2 and creation of direct financial obligations in 2026-Q1. Operating cash flow remains negative, indicating ongoing capital needs. The trajectory reflects persistent capital management efforts.
“Amendment No. 2 to Common Stock Purchase Agreement with White Lion Capital.”
“Created direct financial obligation under note purchase agreement.”
“Unregistered sales of equity securities under Regulation D exemptions.”
Roll out the Shareholder Loyalty Contingent Value Rights program to provide additional shares to eligible shareholders based on price milestones.
Newly stated in 2026-Q2 and 2026-Q2 related disclosures. Management announced and clarified the Shareholder Loyalty CVR program with a record date of August 14, 2026. Nasdaq confirmed no mechanical price adjustment will occur. No financial impact yet visible in revenue or income. The trajectory is early-stage implementation with regulatory clarifications ongoing.
“Clarified Nasdaq has not approved or endorsed the Shareholder Loyalty CVR Program.”
Enhance management team capabilities through executive promotions to support company growth and operations.
Newly stated in 2026-Q2. Management promoted Yeiseok Kim to COO to strengthen leadership. No direct financial metrics linked to this change in the disclosures. The priority is a recent operational focus with limited measurable delivery so far.
“Chief Operating Officer Yeiseok Kim promoted with increased compensation.”
Over the trailing year it converted 0.09x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
35 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.